Alzheimer's Disease(AD) Clinical Trials

10 recruiting

Frequently Asked Questions

Common questions about Alzheimer's Disease(AD) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting

Evaluation of a Neuropsychological Tool to Assess Temporal Processing Abilities in Alzheimer's Disease

Alzheimer's Disease(AD)Time Perception
University Hospital, Caen40 enrolled1 locationNCT07341009
Recruiting
Not Applicable

Social-cognitive Functioning: Validation of a New Neuropsychological Test

Frontotemporal Degeneration(FTD)Alzheimer's Disease(AD)Lewy Body Dementia (LBD)
Assistance Publique - Hôpitaux de Paris120 enrolled1 locationNCT05558709
Recruiting
Not Applicable

COGSCREEN II: Early Detection of Cognitive Impairment

Alzheimer's Disease(AD)
Robert Perneczky400 enrolled1 locationNCT07466394
Recruiting
Not Applicable

Quantification of Hsp90 in the Human Brain

Amyotrophic Lateral Sclerosis(ALS)Alzheimer's Disease(AD)Parkinson's Disease (PD)
Universitaire Ziekenhuizen KU Leuven48 enrolled1 locationNCT07380204
Recruiting

UPenn Observational Research Repository on Neurodegenerative Disease

Corticobasal Syndrome(CBS)Progressive Supranuclear Palsy (PSP)Primary Progressive Aphasia(PPA)+6 more
University of Pennsylvania1,000 enrolled1 locationNCT04715399
Recruiting
Not Applicable

Neuclare Device for Temporary Improvement of Executive Function in Patients With Mild Cognitive Impairment and Prodromal Alzheimer's Disease

Mild Cognitive ImpairmentAlzheimer's Disease(AD)
Deepsonbio138 enrolled3 locationsNCT07239310
Recruiting

Amyloid-β Clearance Mechanisms in Alzheimer's Disease

Alzheimer's Disease(AD)
Ludwig-Maximilians - University of Munich60 enrolled1 locationNCT05059158
Recruiting
Phase 1

Exploring the Utility of [18F]3F4AP for Demyelination Imaging

Alzheimer's Disease(AD)MCIDemyelinating Disorders+3 more
Yale University105 enrolled1 locationNCT06999434
Recruiting
Not Applicable

δ in Dementia Clinical Trials

DementiaCognitive DeclineAlzheimer's Disease(AD)+1 more
The University of Texas Health Science Center at San Antonio200 enrolled1 locationNCT05592678
Recruiting
Early Phase 1

[18F]ACI-19626 PET in TDP-43 Proteinopathies

Amyotrophic Lateral Sclerosis(ALS)Alzheimer's Disease(AD)Frontotemporal Dementia (FTD)+2 more
AC Immune SA45 enrolled1 locationNCT06891716